PCRX Q4 2021 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$159M+21.5% YoY

Gross Profit

$120M75.5% margin

Operating Income

$4M2.6% margin

Net Income

-$5M-3.2% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+24.6%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$14M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$1.3B

Stockholders' Equity

$730M

Cash & Equivalents

$586M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$159M	$131M	+21.5%
Gross Profit	$120M	$96M	+25.6%
Operating Income	$4M	$19M	-77.6%
Net Income	-$5M	$15M	-135.3%